PRESS RELEASES
IQ
Biometrix Announces DOD Defense Research Technologies Grant
FREMONT,
Calif., Oct. 21, 2003
IQ Biometrix Inc. a worldwide provider of integrated law
enforcement and security solutions and Defense Research
Technologies, Inc. announced today a $300,000 Department
of Defense grant. The grant is for the development of a
prototype microfluidic metabolic rate monitor for the US
Army Medical Research and Materiel Command. The monitor
will be easy to use, high performance, continuous, low-cost,
lightweight, and low-power. It will potentially have extensive
applications in biomedical clinical settings, portable field
environments such as the battlefield, security and safety
applications, and biological and chemical counter-terrorism.
IQ Biometrix scientist Michael Polcha will lead IQBM's efforts
in developing and testing this new technology. Tadeusz M.
Drzewiecki, Dr. Eng., an expert in micro-fluidic technologies,
is the principal investigator on the grant. Joseph M. Iseman,
Ph.D. brings experience in both microfluidic systems and
biometrics, and Jerry Calkins, Ph.D., M.D. is a Professor
of Clinical Anesthesiology at the University of Arizona
College of Medicine.
"This
grant and collaboration with the Department of Defense and
DRT cascades well with IQ Biometrix's long-term business
strategy to become a solutions provider. The technology
will expand our existing intellectual property into new
areas of bioanalysis and bioterrorism," said William
Scigliano, CEO and President of IQ Biometrix. "IQBM's
scientists are looking forward to working with DRT on the
Metabolic Rate Monitor and evaluating other technologies
of mutual interest for future collaboration and commercial
applications."
Defense
Research Technologies, Inc., based in Rockville, Maryland,
has been in the lead of fluidic sensors and control systems
development for over eighteen years. DRT is the recipient
of numerous government grants and contracts from the Department
of Defense, National Institutes of Health, and Department
of Energy, and has a proven track record of spinning-off
technology developed with government funding.
About
IQ Biometrix, Inc.
IQ Biometrix,
Inc. (IQBM) provides law enforcement and security technology
solutions for government and private industry. IQ Biometrix,
an innovative California-based company is a leading provider
of facial composite technology for law enforcement agencies
in North America. FACES is currently used by thousands of
policing agencies worldwide, including the Central Intelligence
Agency and the Federal Bureau of Investigation. IQBM is
currently developing new applications based on this foundation
technology tailored to meet the needs of national, business
and personal security. Its solutions practice is focused
on integrating IQBM and partner technologies to provide
customized responses to client needs. Further information
about IQBM can be found at www.iqbiometrix.com.
Safe
Harbor Statement
To the
extent that any of the statements contained herein are forward-looking,
such statements are based on current expectations that involve
a number of uncertainties and risks. Such uncertainties
and risks include, but are not limited to, growth in the
NAS market, market acceptance of products, the development
of new products, the enhancement of existing products, manufacturing
delays, dependence on principal customers, competitive pricing
pressures, product volume and mix, global economic conditions,
dependence on international operations, availability of
key components, timing of orders received, and introduction
of competitor products having technological and/or pricing
advantages. As a result, the Company's operating results
may fluctuate, especially when measured on a quarterly basis.
Actual results may differ materially from such expectations.
Investors are directed to consider other risks and uncertainties
in documents, including forms 8K and 10QSB, filed by the
com! pany with the Securities and Exchange Commission, www.sec.gov.
Contact:
IQ Biometrix, Inc.
Equity Communications
Robert Schechter, 212-499-6809
rschechter@iqbiometrix.com
Back
to Press Releases
